1. In Vivo

Life Technologies Extends Thermo Fisher’s Reach Into Clinical Practice

Thermo Fisher’s $13.6 billion bid for Life Technologies is a blockbuster move within the instrumentation and consumables space, and also has implications for clinical practice. It’s another sign of the growing recognition that integrating clinical workflow is an important potential area for innovation and growth, along with the desire to move genomics tools into clinical use and the development of test content by nontraditional players in diagnostics.

Clearly a blockbuster consolidating move within the instrumentation and consumables space, the April acquisition of Life Technologies Corp. by Thermo Fisher Scientific Inc. is also a sign of the growing recognition that integrating clinical workflow is an important potential area for innovation and growth. As well, it reflects the desire to move genomics tools into clinical use and the interest among nontraditional players in pursuing diagnostics.

Thermo Fisher won a four-month bidding war for LifeTech, agreeing to shell out $13 billion in cash plus assumption of...

More from Global Vision

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.